共 74 条
[1]
Abogunrin S(2015)Budget impact analysis of botulinum toxin a therapy for upper limb spasticity in the United Kingdom Clinicoecon Outcomes Res 7 185-193
[2]
Hortobagyi L(2015)Calculation of standardised unit costs from a societal perspective for health economic evaluation Gesundheitswesen 77 53-61
[3]
Remak E(2001)Long-term survival and causes of death after stroke Stroke 32 2131-2136
[4]
Dinet J(2015)Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study BMJ Open 5 e009358-144
[5]
Gabriel S(2013)Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data Int J Gen Med 6 135-421
[6]
Bakheit AM(2016)Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity Muscle Nerve 53 415-1001
[7]
Bock JO(2015)Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial Lancet Neurol 14 992-441
[8]
Brettschneider C(2013)Management of spasticity revisited Age Ageing 42 435-1926
[9]
Seidl H(2015)Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders Drug Des Dev Ther 9 1913-492
[10]
Bowles D(2011)Efficacy and safety of treatment with incobotulinum toxin a (botulinum neurotoxin type a free from complexing proteins; NT 201) in post-stroke upper limb spasticity J Rehabil Med 43 486-265